Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 10:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 97 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Localized Prostate Adenocarcinoma Clear all
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
Radiation Therapy, Androgen Deprivation Therapy (ADT)
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Prostate Cancer
Interventions
brachytherapy, iodine I 125, radiation therapy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
236
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 184 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced May 21, 2026, 10:10 PM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Cholecalciferol, Laboratory Biomarker Analysis, Patient Observation, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Dietary Supplement · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced May 21, 2026, 10:10 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Prostate CA, Prostate Cancer (Adenocarcinoma), Prostate Cancer Surgery
Interventions
Darolutamide, Relugolix, Radical Prostatectomy
Drug · Procedure
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Prostate Cancer
Interventions
70.2 Gy 3D-CRT/IMRT, 79.2 Gy 3D-CRT/IMRT
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
1,534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2022
U.S. locations
72
States / cities
Long Beach, California • Sacramento, California • San Francisco, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced May 21, 2026, 10:10 PM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma), Prostate Cancer (Diagnosis), Prostate Cancer Metastatic Disease
Interventions
PSMA PET/CT scan
Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced May 21, 2026, 10:10 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Prostate Adenocarcinoma, Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation, Recurrent Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate, Apalutamide, Leuprolide Acetate, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Drug · Other · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced May 21, 2026, 10:10 PM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Cancer
Interventions
management of therapy complications, massage therapy, pain therapy, psychosocial assessment and care, quality-of-life assessment
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2017 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage II Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
abiraterone acetate, prednisone, leuprolide acetate, laboratory biomarker analysis, external beam radiation therapy, goserelin acetate
Drug · Other · Radiation
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Seattle, Washington • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced May 21, 2026, 10:10 PM EDT
Terminated Early Phase 1 Interventional
View directory record Official record
Conditions
Cancer
Interventions
cyclophosphamide, Cryoablation
Drug · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2019 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Prostate Cancer Recurrent, Prostate Cancer, Prostate Adenocarcinoma
Interventions
Epidiolex Oral Liquid Product
Drug
Lead sponsor
Zin W Myint
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced May 21, 2026, 10:10 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions
diffusion-weighted magnetic resonance imaging, laboratory biomarker analysis
Procedure · Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2014 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
NanoPac®
Drug
Lead sponsor
NanOlogy, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix, Distal Urethral Cancer, Fallopian Tube Cancer, Gastrinoma, Glucagonoma, Inflammatory Breast Cancer, Insulinoma, Liver Metastases, Localized Unresectable Adult Primary Liver Cancer, Lung Metastases, Male Breast Cancer, Malignant Pericardial Effusion, Malignant Pleural Effusion, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Parathyroid Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Newly Diagnosed Carcinoma of Unknown Primary, Occult Non-small Cell Lung Cancer, Pancreatic Polypeptide Tumor, Primary Peritoneal Cavity Cancer, Proximal Urethral Cancer, Pulmonary Carcinoid Tumor, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adrenocortical Carcinoma, Recurrent Adult Primary Liver Cancer, Recurrent Anal Cancer, Recurrent Bladder Cancer, Recurrent Breast Cancer, Recurrent Carcinoma of Unknown Primary, Recurrent Cervical Cancer, Recurrent Colon Cancer, Recurrent Endometrial Carcinoma, Recurrent Esophageal Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Pancreatic Cancer, Recurrent Parathyroid Cancer, Recurrent Prostate Cancer, Recurrent Rectal Cancer, Recurrent Renal Cell Cancer, Recurrent Salivary Gland Cancer, Recurrent Small Intestine Cancer, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Thyroid Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer, Skin Metastases, Small Intestine Adenocarcinoma, Somatostatinoma, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Adrenocortical Carcinoma, Stage III Bladder Cancer, Stage III Cervical Cancer, Stage III Colon Cancer, Stage III Endometrial Carcinoma, Stage III Esophageal Cancer, Stage III Follicular Thyroid Cancer, Stage III Gastric Cancer, Stage III Malignant Testicular Germ Cell Tumor, Stage III Mucoepidermoid Carcinoma of the Oral Cavity, Stage III Ovarian Epithelial Cancer, Stage III Pancreatic Cancer, Stage III Papillary Thyroid Cancer, Stage III Prostate Cancer, Stage III Rectal Cancer, Stage III Renal Cell Cancer, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Vaginal Cancer, Stage III Vulvar Cancer, Stage IIIA Anal Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Anal Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Adrenocortical Carcinoma, Stage IV Anal Cancer, Stage IV Bladder Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Endometrial Carcinoma, Stage IV Esophageal Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Gastric Cancer, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Pancreatic Cancer, Stage IV Papillary Thyroid Cancer, Stage IV Prostate Cancer, Stage IV Rectal Cancer, Stage IV Renal Cell Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Stage IVB Vulvar Cancer, Thyroid Gland Medullary Carcinoma, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer, Urethral Cancer Associated With Invasive Bladder Cancer, WDHA Syndrome
Interventions
recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced May 21, 2026, 10:10 PM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, CT-guided Stereotactic Body Radiation Therapy, Inter-fraction Adaptation of Treatment Plan, Magnetic Resonance Imaging, MRI-guided Stereotactic Body Radiation Therapy, Survey Administration
Procedure · Radiation · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Prostate Cancer
Interventions
soy isoflavones, soy protein isolate, placebo
Dietary Supplement · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced May 21, 2026, 10:10 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Prostate Cancer
Interventions
Intensity-Modulated Radiation Therapy (IMRT), Docetaxel+IMRT
Radiation · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2023
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions
Bicalutamide, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Therapeutic Conventional Surgery, Vorinostat
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, mitoxantrone hydrochloride, conventional surgery
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced May 21, 2026, 10:10 PM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Radiation Toxicity, Sexual Dysfunction
Interventions
Stereotactic Body Radiation Therapy with Integrated Boost
Radiation
Lead sponsor
John Fiveash, MD
Other
Eligibility
19 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced May 21, 2026, 10:10 PM EDT
Withdrawn Not applicable Interventional
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Interventions
High-Dose Rate Brachytherapy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Radiation · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced May 21, 2026, 10:10 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Relacorilant, Enzalutamide, Placebo (Sugar Pill), Androgen Deprivation Therapy, Radical Prostatectomy
Drug · Other · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Chicago, Illinois • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Cancer
Interventions
trastuzumab, tipifarnib
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Fort Sam Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced May 21, 2026, 10:10 PM EDT